150 related articles for article (PubMed ID: 34047051)
1. Immune thrombocytopenia in two infant cases managed with eltrombopag.
Ceglie G; Nocentini G; De Gennaro F; Clemente V; Di Mauro M; Palumbo G
Pediatr Blood Cancer; 2021 Sep; 68(9):e29120. PubMed ID: 34047051
[No Abstract] [Full Text] [Related]
2. Eltrombopag for chronic immune thrombocytopenia.
Milosevic I; Slade E; Drysdale H;
Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
[No Abstract] [Full Text] [Related]
3. Immune thrombocytopenic purpura--from agony to agonist.
Schwartz RS
N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
[No Abstract] [Full Text] [Related]
4. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
Grainger JD;
Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
[No Abstract] [Full Text] [Related]
5. Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis.
Ahmed HAW; Masoud AT; Han J; Adel Sofy A; Saeed Ahmed A; Abdesattart AT; Drokow EK; Sun K
Clin Appl Thromb Hemost; 2021; 27():10760296211005555. PubMed ID: 33874785
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag in thrombocytopenia.
Zimmer J; Hentges F; Andrès E
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
[No Abstract] [Full Text] [Related]
7. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.
Sartori R; Candiotto L; Ruggeri M; Tagariello G
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s151-2. PubMed ID: 24120607
[No Abstract] [Full Text] [Related]
8. A comment on Boyers et al.: "eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal".
Allen R; Brainsky A; Grotzinger K; Roccia T
Pharmacoeconomics; 2013 Jan; 31(1):87-9. PubMed ID: 23329595
[No Abstract] [Full Text] [Related]
9. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Panzer S
Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
[TBL] [Abstract][Full Text] [Related]
10. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
[TBL] [Abstract][Full Text] [Related]
11. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
Jolliffe E; Romeril K
Intern Med J; 2014 Jul; 44(7):697-9. PubMed ID: 25041772
[TBL] [Abstract][Full Text] [Related]
12. Acute Myocardial Infarction Due to Eltrombopag Therapy in a Patient with Immune Thrombocytopenic Purpura.
Sert S; Özdil H; Sünbül M
Turk J Haematol; 2017 Mar; 34(1):107-108. PubMed ID: 27956373
[No Abstract] [Full Text] [Related]
13. Successful eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease.
El Rassy E; Kourie HR; Nehme W; Georges S; Haddad E; Nasnas R; Nasr F
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):e23-4. PubMed ID: 25497274
[No Abstract] [Full Text] [Related]
14. Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency.
Scaramucci L; Niscola P; Palombi M; Tendas A; Giovannini M; Fabritiis Pd
Turk J Haematol; 2016 Mar; 33(1):77-8. PubMed ID: 27091587
[No Abstract] [Full Text] [Related]
15. Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.
Moulis G; Germain J; Rueter M; Lafaurie M; Aroichane M; Comont T; Mahévas M; Viallard JF; Chèze S; Ebbo M; Audia S; Leclerc-Teffahi S; Sommet A; Beyne-Rauzy O; Michel M; Godeau B; Lapeyre-Mestre M;
Am J Hematol; 2022 Feb; 97(2):E40-E44. PubMed ID: 34779031
[No Abstract] [Full Text] [Related]
16. Update on eltrombopag for ITP.
Bussel JB
Oncology (Williston Park); 2009 Nov; 23(13):1177-8. PubMed ID: 20043469
[No Abstract] [Full Text] [Related]
17. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Panzer S; Pabinger I
Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614
[No Abstract] [Full Text] [Related]
19. The authors' reply to Allen et al.: "A Comment on Boyers et al.: 'eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal'".
Boyers D; Jia X; Jenkinson D; Mowatt G
Pharmacoeconomics; 2013 Jan; 31(1):91. PubMed ID: 23329596
[No Abstract] [Full Text] [Related]
20. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
Wang X; Liu X; Wang L; Wang JY; Li A
Blood Coagul Fibrinolysis; 2019 Mar; 30(2):71-74. PubMed ID: 30720490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
